Strong support for pro-rata Rights Offer

We’re pleased to share an encouraging update on our current pro rata rights offer. Thanks to the strong backing from our shareholder community, Rua Bioscience has already secured over $1.5 million in commitments from existing investors. With $2 million available under the offer, this early momentum reflects your confidence in our direction and the progress we are making across the business.

Your support signals belief in Rua’s commercial execution, our expanding international footprint, and the long-term growth opportunities we are pursuing in the global medicinal cannabis market. We are humbled by this response and remain focused on delivering against the strategy you have endorsed.

Offer Still Open – Closes Friday, 12 December 2025

A reminder that the pro rata rights offer remains open until end of day, Friday 12 December 2025. If you wish to participate, please ensure your application is submitted before the closing date.

Full details—including the offer timetable, eligibility, and instructions on how to take up your rights—can be found in the Offer Document at:

www.ruabio.com/capital-raise-november-2025

How Your Investment Will Drive Growth

Funds raised through this offer will support Rua’s next phase of growth, including:

• Strengthening working capital

• Expanding marketing activities

• Launching and commercialising new products in key international markets, including Germany, Australia, the UK, and Czechia

These initiatives position Rua to accelerate its commercial progress and build sustainable long-term value for shareholders, all around the motu.

Thank you once again for your continued support. We look forward to keeping you updated as we advance toward our goals.